All In Biotech

Drug Trial Radar · NCT00242710

Study Evaluating Bazedoxifene/Conjugated Estrogens Combinations In Postmenopausal Women

A Double-Blind, Randomized, Placebo- And Active-Controlled Efficacy And Safety Study Of Bazedoxifene/Conjugated Estrogens Combinations For Prevention Of Endometrial Hyperplasia And Prevention Of Osteoporosis In Postmenopausal Women

Last checked: Nov 20, 2026Latest source record: Dec 20, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,083 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,083

Actual

Start

Sep 2005

Primary completion

Sep 2008

Study completion Sep 2008

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Oct 20, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Prevention
Who can join
Female only, from 40 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine whether bazedoxifene/conjugated estrogens combinations are effective for the prevention of endometrial hyperplasia and for the prevention of osteoporosis in postmenopausal women.

Conditions

  • Endometrial Hyperplasia
  • Osteoporosis

Interventions

  • Bazedoxifene/Conjugated EstrogenDrug

    Subjects will take 1 capsule orally, once daily, at approximately the same time each day continuously for the duration of the study.

  • Bazedoxifene/Conjugated EstrogenDrug

    Subjects will take 1 capsule orally, once daily, at approximately the same time each day continuously for the duration of the study.

  • CE 0.45 mg/MPA 1.5mgDrug

    Subjects will take 1 capsule orally, once daily, at approximately the same time each day continuously for the duration of the study.

  • PlaceboOther

    Subjects will take 1 capsule orally, once daily, at approximately the same time each day continuously for the duration of the study.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Hyperplasia at ScreeningTime frame: Screening
  2. Percentage of Participants With Hyperplasia at Month 12Time frame: Month 12
  3. Bone Mineral Density (BMD) of Lumbar Spine at ScreeningTime frame: Screening
  4. Percent Change From Baseline in Bone Mineral Density (BMD) of Lumbar Spine at Month 12Time frame: Baseline, Month 12
  5. Bone Mineral Density (BMD) of Total Hip at ScreeningTime frame: Screening
  6. Percent Change From Baseline in Bone Mineral Density (BMD) of Total Hip at Month 12Time frame: Baseline, Month 12

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • Pfizer Investigational Site

    Upland, California

  • Pfizer Investigational Site

    Inverness, Florida

  • Pfizer Investigational Site

    West Palm Beach, Florida

  • Pfizer Investigational Site

    Decatur, Georgia

  • Pfizer Investigational Site

    Honolulu, Hawaii

  • Pfizer Investigational Site

    Lexington, Kentucky

  • Pfizer Investigational Site

    Billings, Montana

  • Pfizer Investigational Site

    Eugene, Oregon

  • Pfizer Investigational Site

    Pittsburgh, Pennsylvania

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.